Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Date:12/9/2008

y also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully complete clinical trials for KRX-0401; our ability to meet anticipated development timelines for KRX-0401 due to recruitment, clinical trial results, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
4. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
5. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
6. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
7. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
8. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
9. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
10. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
11. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... BEIJING , March 30, 2015 A ... high-resolution atomic structure of a cell-surface receptor that plays ... This research unexpectedly discloses many new structural features, which ... protein-coupled receptors (GPCRs) and open a new door for ... in Nature on March 30, the researchers ...
(Date:3/30/2015)... 26, 2015 Research and Markets ... the "Marine Biotechnology - Global Strategic Business ... Annual estimates and forecasts are provided for the ... analysis is provided for these markets. Market data ... research. This report analyzes the worldwide ...
(Date:3/30/2015)... DIEGO , March 30, 2015  Orexigen ... that Tom Cannell has joined as ... global commercialization of Contrave® /Mysimba™ (naltrexone HCl / ... aspects of Orexigen,s global commercial strategy, assuming responsibilities ... successfully leading Orexigen,s commercial effort through the U.S. ...
Breaking Medicine Technology:New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 2New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 3New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 4New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 5New Molecular Structures Challenge Conventional Concepts of Drug Action at Receptors 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 2Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 3Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 4Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 5Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 6Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 7Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 8Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 9Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer 10
... LOUIS, Oct. 14 Young Innovations, Inc. (Nasdaq: YDNT ) ... with a live and on-demand web cast conference call on Thursday, ... audio broadcast of the call will be available through InterCall at ... audio broadcast will also be available through the Company,s website, ...
... Oct. 14 In the United States, a woman is ... American Cancer Society. Except for skin cancers, breast cancer ... , To help fight this disease, eMed-ID, the ... for every pink Personal Health Records (PHR) wristband sold to ...
Cached Medicine Technology:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available 2Breast Cancer Survivors and Patients Encouraged to Have Medical History Readily Available 3
(Date:3/30/2015)... In a recent report published by SF ... championing effective drug and alcohol treatment for victims suffering ... funds to stabilize the addiction treatment programs, and continue ... and alcohol addiction. Harbor Village Detox is extending its ... disorders in New Jersey, in hopes to help circumvent ...
(Date:3/30/2015)... 30, 2015 Follow us on ... to develop and establish chronic pain rehabilitation centers are ... the market is poised to benefit from the rise ... the increase in chronic health conditions such as Cancer, ... among others. While conventional treatment for pain management is ...
(Date:3/30/2015)... York (PRWEB) March 30, 2015 Recently, ... 10 Exotic Water Awards, with the top three winners being ... listed on the company’s website, along with other informative information ... water, glacial water, spring water, mineral water and sparkling water ... is one of the top exotic water brands highlighted ...
(Date:3/30/2015)... Valerie Harper, the actress best known as ... Mary Tyler Moore Show,” will be the keynote speaker ... magazine announced today. Harper, who is living with terminal ... 40th Annual Congress on April 23 in Orlando, Fla. ... play in the lives of people with cancer. Nominated ...
(Date:3/30/2015)... DMG Productions announces the upcoming airing of ... Monday, April 20, 2015 at 7:30 a.m. ET and ... this episode Innovations will explore Limbkeepers® non compression knit ... skin on arms, hands, and legs from abrasion, skin ... their products help reduce injuries, allow for continued daily ...
Breaking Medicine News(10 mins):Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Technological Developments, Better Patient Awareness & Affordability Drive the Pain Management Devices Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Best Exotic Water Brands Acclaimed by 10 Best Water 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3Health News:New Episode of Innovations Airing Monday, April 20, 2015 Via Discovery Channel 2
... Zipfizz products gain enhanced presence in Alaska and the Pacific ... ... Zipfizz Corporation, the,makers of Zipfizz(R), the healthy energy drink mix that has ... Odom Corporation will begin distributing its product line in,Alaska, Washington and Oregon., ...
... revealing the inner workings of a common cell-to-cell ... new clues about mysterious and contentious creatures called ... implications for a high-profile breast-cancer drug trial getting ... other institutions. , In the groundbreaking trial, researchers ...
... study finds , , WEDNESDAY, April 9 (HealthDay News) -- ... women with mild to moderate chronic kidney disease (CKD), ... new study. , The use of osteoporosis drugs in ... known if the drugs were safe for these women. ...
... WASHINGTON, April 9, 2008 Reflecting the,growing concern ... confidence in being able to afford a comfortable ... unmatched in the 18 years of the,Retirement Confidence ... percentage of workers very confident about having enough ...
... WASHINGTON, April 9, 2008 Medicaid Dental,Center (MDC), ... Carolina,previously known as Smile Starters and Carolina Dental ... and North Carolina to resolve False,Claims Act allegations, ... agreed to pay $10,050,000 to resolve allegations that ...
... 9, 2008 More than 46 million,people -- ... States report having a form,of doctor-diagnosed arthritis.(1) Many ... face dexterity challenges when changing their hearing aid,battery. ... organization committed to the health and well being ...
Cached Medicine News:Health News:Zipfizz(R) Announces Distribution Deal With the Odom Corporation 2Health News:Secrets of cellular signaling shed light on new cancer stem cell therapies 2Health News:Raloxifene Safe for Women With Decreased Kidney Function 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 3Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 4Health News:North Carolina Dental Services Chain Pays $10 Million to Resolve False Claims Allegations 2Health News:Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery 2Health News:Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery 3Health News:Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery 4
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
Medicine Products: